

**REMARKS*****Claim Amendments***

The allowance of claims 6-8 is noted with appreciation.

Claims 1-5 have been cancelled, claim 6 has been amended and new claims 9-12 have been added.

Claim 6 has been placed in independent form by incorporating the limitations of now-cancelled claim 4 upon which it was dependent.

New claims 9 and 10, dependent on claim 6, more specifically recite the chlorosilane component as disclosed at page 3, lines 5-8 of the specification.

New claims 11 and 12, dependent on claims 6 and 11, respectively, more specifically recite the nitrogenous base component as disclosed at page 3, lines 2-4 of the specification.

Clearly no new matter has been added, and entry of these amendments is respectfully requested. Following entry of these amendments, claims 6-12 are pending in this application.

***Claim Rejections - 35 USC § 103***

At page 2 of the Action, claims 1-6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Alstermark et al (WO 03/051826) in view of Rossen et al (5,663,341) or Alstermark et al alone. However, on the Office Action Summary it is stated that claims 6-8 *are allowed*, and only claims 1-5 are rejected. Consistent with the Office Action Summary, the Examiner states on page 3 under "Allowable Subject Matter" that "Claims 6-8 are allowed." Accordingly, it is understood that claims 6-8 are allowed, and that the statement on page 2 that claims 1-6 are rejected under 35 U.S.C. 103(a) was intended to only apply to claims 1-5.

With this understanding, the rejection of claims 1-5 has been obviated by the cancellation of these claims.

### ***Allowable Subject Matter***

Applicants note with appreciation that claims 6-8 are allowed. By the above amendments, claim 6 has been placed in independent form by incorporating the limitations of now-cancelled claim 4 upon which it was dependent, which should not in any way detract from the allowance of claim 6. New dependent claims 9-12 have been added, which further limit the process of claim 6 with respect more specific chlorosilane or nitrogenous base components. Specification support for these new claims is identified above under the ***Claim Amendments*** heading. Inasmuch as these new claims are dependent on allowed claim 6 and fully supported by the specification disclosure, it is believed that new claims 9-12 should be allowable as well.

### ***Conclusion***


The rejection of claims 1-5 has been obviated by the cancellation of these claims. Claims 6-8 have been allowed. New claims 9-12 add further limitations to the process of allowed claim 6, which limitations are fully supported by the specification disclosure. Therefore all of currently pending claims 6-12 are believed to be allowed and/or clearly allowable. Accordingly, allowance of all claims and a Notice of Allowance to that effect are believed to be in order and are respectfully requested.

However, if any issue remains outstanding after consideration of the above, it is respectfully requested that the Examiner telephone the undersigned to explore whether an expedited resolution might be obtained.

**EXCEPT** for issue fees payable under 37 C.F.R. § 1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit

Account 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully Submitted,  
**Morgan Lewis & Bockius LLP**



By: \_\_\_\_\_

Donald J. Bird  
Registration No. 25,323  
Tel. No.: (202) 739-5320  
Fax No.: (202) 739-3001

Date: December 18, 2007  
Morgan Lewis & Bockius LLP  
Customer No. **09629**  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel. No.: 202-739-3000  
DJB: